Hep C Transplant Patients Benefit from New Therapy

the MPR take:

Liver transplant patients with recurring hepatitis C virus (HCV) have often experienced poor results from treatment, but a new study shows promise for effective therapy for this population. In data presented at the International Liver Congress 2014, 104 post-liver transplant patients with recurring HCV, poor clinical prognoses, and no remaining treatment options received sofosbuvir (SOF) and ribavirin (RBV) with pegylated interferon (PEG) (included at the doctors’ discretion) for >48 weeks. 62% had a sustained viral response after 12 weeks of treatment (SVR12) and 62% of patients saw improvement in clinical conditions associated with hepatic decompensation and/or benefits in liver function tests. 

Hep C Transplant Patients Benefit from New Therapy
Hep C Transplant Patients Benefit from New Therapy
London, United Kingdom, Friday 11 April 2014: New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).[1] As part of a compassionate use program, 104 ...

READ FULL ARTICLE From virtualpressoffice.easl.eu

Loading links....